BioCardia, Inc.
BCDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | -87.8% | -64.7% | 33.2% | – |
| Cost of Goods Sold | $4 | $8 | $9 | $1 |
| Gross Profit | -$4 | -$7 | -$7 | $0 |
| % Margin | -7,463.8% | -1,519.7% | -553.4% | 36.9% |
| R&D Expenses | $4 | $8 | $9 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$3 | -$4 | -$1 |
| Operating Expenses | $4 | $4 | $4 | $13 |
| Operating Income | -$8 | -$12 | -$12 | -$13 |
| % Margin | -13,794.8% | -2,441.1% | -880.3% | -1,244.3% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$8 | -$12 | -$12 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$12 | -$12 | -$13 |
| % Margin | -13,700% | -2,425.8% | -880.7% | -1,243.4% |
| EPS | -2.9 | -8.19 | -10.05 | -11.19 |
| % Growth | 64.6% | 18.5% | 10.2% | – |
| EPS Diluted | -2.9 | -8.19 | -10.05 | -11.19 |
| Weighted Avg Shares Out | 3 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 3 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$12 | -$12 | -$13 |
| % Margin | -13,679.3% | -2,423.5% | -874.2% | -1,238.4% |